Rockpointe, American Kidney Fund team up for Kidney Summit 2019

Registration is open for Kidney Summit 2019, a collaboration between Rockpointe and the American Kidney Fund that is designed to update clinicians about the latest treatments, guidelines, and quality measures regarding chronic kidney disease (CKD) care. This free continuing medical education (CME) activity, intended for nephrologists and nurse practitioners who diagnose and manage patients with or at risk of CKD, will be held Sunday, October 27, at the University of North Texas Health Science Center in Fort Worth, TX; Friday, November 15, at Georgia State University in Atlanta, GA; and Sunday, December 8, at the University of Illinois in Chicago, IL. Each summit features three sessions offering a total of 4.5 hours of CME, ANCC, and MIPS credits, and is eligible for American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points.

• Session 1: “Role of the SGLT2 Inhibitors in Patients with T2DM, CKD, and CVD.” Recently published data have revealed that sodium-glucose cotransporter-2 (SGLT2) inhibitors have the potential to prevent CKD progression in patients with type II diabetes mellitus (T2DM) and CKD. This activity will help participants better understand and apply the renal outcomes data with SGLT2 inhibitors to optimize T2DM and CKD treatment plans and to deliver the most up-do-date care.
• Session 2: “ADVENT OF THE HIF-PHIs: Key Considerations for Anemia of CKD Care.” Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of drugs in late-stage trials that might soon shift the balance of treatment for anemia of CKD. These oral agents are well tolerated, unlike red-cell transfusions and conventional erythropoiesis-stimulating agents (ESAs). In addition, HIF-PHIs, unlike ESAs, are able to increase hemoglobin (Hgb) levels irrespective of iron supplementation or inflammatory status. This activity will help participants evaluate the risks and benefits of conventional treatments for anemia of CKD, as well as the latest evidence and potential roles of the HIF-PHIs, so that, upon approval, they can be properly incorporated into patient care.
• Session 3: “Navigating the Executive Order on Advancing American Kidney Health.” Many clinicians might be unaware of President Trump’s executive order, issued in July, that aims to improve the diagnosis and treatment of patients with CKD and end-stage renal disease (ESRD) and, ultimately, to improve outcomes for patients. This activity will review the order and associated report and will discuss strategies for improving patient care and issues related to reimbursement for the management of patients with CKD and ESRD

Supported by an educational grant from AstraZeneca Pharmaceuticals LP in collaboration with FibroGen, these activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine, Rockpointe and the Postgraduate Institute for Medicine. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combatting the nation’s opioid crisis, and utilizing technical advances that improve care. As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy and Medicine. At Rockpointe, education equals quality.

To learn more about Kidney Summit 2019 and reserve your space, go to https://www.rockpointe.com/kidney-summit-2019/or click here.